{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:44:40Z","timestamp":1762875880927},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.atherosclerosissup.2017.05.005","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T22:16:39Z","timestamp":1496355399000},"page":"44-49","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?"],"prefix":"10.1016","volume":"30","author":[{"given":"V.J.J.","family":"Schettler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ringel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Julius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Klingel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Heigl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Roeseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gr\u00fctzmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib1","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1161\/ATVBAHA.115.306442","article-title":"Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB council","volume":"35","author":"Hegele","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib2","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.ijcard.2013.03.149","article-title":"Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease","volume":"168","author":"Calling","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib9","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s15027-015-0637-5","article-title":"Differenzierung der Indikation zur Lipoproteinapherese bei erh\u00f6htem Lp(a) durch unterschiedliche Messmethoden: Lp(a)-Masse versus Lp(a)-Partikelanzahl","volume":"3","author":"Schettler","year":"2015","journal-title":"Cardiovasc"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lp(a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11789-012-0046-6","article-title":"Current view: indications for extracorporeal lipid apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib14","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib16","first-page":"3321","article-title":"Publication of a decision of Federal Joint Committee on apheresis for isolated Lp(a)-elevation with progressive cardiovascular disease","volume":"138","author":"German Federal Ministry of Health","year":"2008","journal-title":"Trans Ger Fed Minist (BAnz)"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib17","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib18","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and Apo(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1744-9987.2006.00441.x","article-title":"Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment","volume":"10","author":"Mellwig","year":"2006","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosissup.2012.10.017","article-title":"Lipoprotein apheresis\u2013more than just cholesterol reduction?","volume":"14","author":"Neumann","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1532-429X-14-80","article-title":"Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR\u2013a comparative analysis","volume":"14","author":"Grimm","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.atherosclerosissup.2015.02.033","article-title":"Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run","volume":"18","author":"Gross","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosissup.2015.02.006","article-title":"First data from the German Lipoprotein Apheresis Registry (GLAR)","volume":"18","author":"Schettler","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib28","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosissup.2015.02.035","article-title":"Mental symptoms and quality of life in lipoprotein apheresis patients in comparison to hemodialysis patients, platelet donors and normal population","volume":"18","author":"Stasiewski","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1526-0968.2003.00120.x","article-title":"State of the art of low-density lipoprotein apheresis in the year 2003","volume":"8","author":"Bosch","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosissup.2015.02.013","article-title":"Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany","volume":"18","author":"Heigl","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib33","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2362.1994.tb01068.x","volume":"24","author":"Schuff-Werner","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11789-015-0073-1","article-title":"Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels","volume":"10","author":"Schettler","year":"2015","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosissup.2012.10.005","article-title":"Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern","volume":"14","author":"von Dryander","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib37","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing\u00a0lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib39","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib40","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/1060028015608487","article-title":"Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab","volume":"49","author":"White","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.atherosclerosissup.2014.07.004","article-title":"Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.atherosclerosissup.2017.05.005_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-0035-1555713","article-title":"Jenseits der LDL-Cholesterin- und Lp(a)-Absenkung \u2013 Pleiotrope Effekte der Lipoproteinapherese auf das intravasale System?","volume":"19","author":"Schettler","year":"2015","journal-title":"Dialyse aktuell"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568817300478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568817300478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T03:01:02Z","timestamp":1535770862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568817300478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":42,"alternative-id":["S1567568817300478"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.005","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}